Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 501–600 of 1,010
Advances in artificial intelligence to predict cancer immunotherapy efficacy
Xie, J., Luo, X., Deng, X., Tang, Y., Tian, W., Cheng, H., Zhang, J., Zou, Y., Guo, Z., & Xie, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1076883 · Cited by 118
“(39) found that individual response rates to antiCTLA4 correlated with TMB and cytolytic markers.”
BackgroundPrognostic value of B cells in cutaneous melanoma
Selitsky, S. R., Mose, L. E., Smith, C. C., Chai, S., Hoadley, K. A., Dittmer, D. P., Moschos, S. J., Parker, J. S., & Vincent, B. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0647-5 · Cited by 120
“To address these gaps in our knowledge, we analyzed RNA-seq data from the complete TCGA SKCM tumor dataset (n = 473 tumors) [17] as well as publicly available RNA-seq data from tumor tissues that were collected prior to treatment with immune checkpoint inhibitors [8, 28].”
BackgroundMethodThe immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Chen, H., Chong, W., Teng, C., Yao, Y., Wang, X., & Li, X. (2019) · Cancer Science · doi:10.1111/cas.14113 · Cited by 115
Radioimmunotherapy for the treatment of head and neck cancer
Karam, S. D., & Raben, D. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30306-7 · Cited by 108
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 105
“[14] showed that the number of nonsynonymous mutations per tumor correlated with clinical responses in ipilimumab-treated melanoma patients in their whole exome analysis of 110 pretreatment”
BackgroundMeningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications
Bi, W. L., Zhang, M., Wu, W. W., Mei, Y., & Dunn, I. F. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00040 · Cited by 106
“Deployment of the innate and adaptive immune response offers an attractive option for genomically complex tumors, where presumably a higher neoantigen load is available for immune targeting (45, 46).”
BackgroundAn Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Lu, Y.-C., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 103
Lamble, A. J., Kosaka, Y., Laderas, T., Maffit, A., Kaempf, A. J., Brady, L., Wang, W., Long, N., Saultz, J. N., Mori, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916206117 · Cited by 102
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Litchfield, K., Reading, J. L., Lim, E. L., Xu, H., Liu, P., Bakir, M. A., Wong, Y. N. S., Rowan, A., Funt, S. A., Merghoub, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17526-5 · Cited by 112
“Tumor mutation burden (TMB) is associated with response to immunotherapy across multiple tumor types, and therapeutic modalities, including checkpoint inhibitors (CPIs) and cellular based therapy (1-8) (9, 10).”
BackgroundMethodGogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.004 · Cited by 102
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Zanetti, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.67 · Cited by 109
van Vloten, J. P., Workenhe, S. T., Wootton, S. K., Mossman, K. L., & Bridle, B. W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701021 · Cited by 116
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 110
Tray, N., Weber, J. S., & Adams, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0214 · Cited by 105
“Several studies demonstrated the association of the mutational landscape of tumors with responsiveness to PD-1 blockade in NSCLC (19) and anti–CTLA-4 therapy in melanoma (20, 21).”
BackgroundThe odds of immunotherapy success
Gubin, M. M., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aad4140 · Cited by 101
Sridharan, V., Gjini, E., Liao, X., Chau, N. G., Haddad, R. I., Severgnini, M., Hammerman, P. S., El‐Naggar, A. K., Freeman, G. J., Hodi, F. S., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0031 · Cited by 102
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Wu, H., Chen, Y., Wang, Z.-X., Zhao, Q., He, M.-M., Wang, Y.-N., Wang, F., & Xu, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0737-3 · Cited by 107
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
Roelands, J. P., Hendrickx, W., Zoppoli, G. M., Mall, R., Saad, M., Halliwill, K. D., Curigliano, G., Rinchai, D., Decock, J. V., Delogu, L. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000617 · Cited by 108
Haddad, R. I., Seiwert, T. Y., Chow, L. Q. M., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B. A., Tahara, M., Keam, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003026 · Cited by 118
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 133
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 144
Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240859 · Cited by 100
“An interesting aspect in the study by Hiraoka et al. is the distinction between peritumoral and intratumoral TLS, and the association of intra-tumoral TLS with prolonged overall survival,44 which is in line with Castino et al.45 and similar findings for other cancers.46-48 Evaluation of our own data substantiated the…”
BackgroundSelf-citationImmune checkpoint inhibitors for metastatic bladder cancer
Massari, F., Nunno, V. D., Cubelli, M., Santoni, M., Fiorentino, M., Montironi, R., Cheng, L., López-Beltrán, A., Battelli, N., & Ardizzoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.007 · Cited by 107
“Indeed, tumours with low mutational load are associated with lower expression of cancer associated antigen/neo-antigen leading to small or absent tumour associated immune-infiltrate and lower activated T-Cells and Memory T-Cells resulting in a PD-1/PD-L1 and CTLA-4 inhibition escape [30-36].”
BackgroundFerroptosis‐related gene signature predicts prognosis and immunotherapy in glioma
Wan, R., Wang, P., Xia, Q., Zhou, H., & Mao, X. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13654 · Cited by 115
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
In, G. K., Hu, J. S., & Tseng, W. W. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017712963 · Cited by 101
Mutation position is an important determinant for predicting cancer neoantigens
Capietto, A.-H., Jhunjhunwala, S., Pollock, S. B., Lupardus, P. J., Wong, J., Hänsch, L., Cevallos, J., Chestnut, Y., Fernandez, A., Lounsbury, N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190179 · Cited by 110
“…blockade immunotherapies (Rizvi et al., 2015; Snyder et al., 2014), and high neoantigen or mutation burden is generally predictive of response to checkpoint blockade (Hellmann et al., 2018; Le et al., 2015; Nathanson et al., 2017; Rizvi et al., 2015; Snyder et al., 2014; Van Allen et al., 2015).”
BackgroundThe neoepitope landscape in pediatric cancers
Chang, T., Carter, R. A., Li, Y., Li, Y., Wang, H., Edmonson, M. N., Chen, X. '., Arnold, P. Y., Geiger, T. L., Wu, G., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0468-3 · Cited by 112
Rhee, J., Jung, Y. C., Kim, K. R., Yoo, J., Kim, J., Lee, Y., Ko, Y. H., Lee, H. H., Cho, B. C., & Kim, T. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0201 · Cited by 112
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 98
Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd8636 · Cited by 97
“dataset (11) with low neoantigen burdens.”
BackgroundSelf-citationMcGrail, D. J., Federico, L., Li, Y., Dai, H., Lu, Y., Mills, G. B., Yi, S., Lin, S.-Y., & Sahni, N. (2018) · Nature Communications · doi:10.1038/s41467-018-03730-x · Cited by 95
The neoepitope landscape of breast cancer: implications for immunotherapy
Narang, P., Chen, M., Sharma, A. A., Anderson, K. S., & Wilson, M. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5402-1 · Cited by 101
Monoclonal Antibodies for the Treatment of Cancer
Pento, J. T. (2017) · Anticancer Research · doi:10.21873/anticanres.12040 · Cited by 129
Kazdal, D. N., Endris, V., Allgäuer, M., Kriegsmann, M., Leichsenring, J., Volckmar, A., Harms, A., Kirchner, M., Kriegsmann, K., Neumann, O., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.006 · Cited by 100
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Ghorani, E., Reading, J. L., Henry, J. Y., Massy, M. R. D., Rosenthal, R., Turati, V., Joshi, K., Furness, A. J. S., Ben Aissa, A., Saini, S. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0066-y · Cited by 96
Li, T., Liu, T., Zhu, W., Xie, S., Zhao, Z., Feng, B., Guo, H., & Yang, R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211035540 · Cited by 112
Multiomics and spatial mapping characterizes human CD8 + T cell states in cancer
Naulaerts, S., Datsi, A., Borràs, D., Antoranz, A., Messiaen, J., Vanmeerbeek, I., Sprooten, J., Laureano, R. S., Govaerts, J., Panovska, D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1016 · Cited by 100
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 94
“Validation set variants (3, 4, 16) were re-annotated using SnpEff (version 4.”
BackgroundMethodInfluentialCharacterization of the Neuroendocrine Tumor Immune Microenvironment
da Silva, A., Bowden, M., Zhang, S., Masugi, Y., Thorner, A. R., Herbert, Z. T., Zhou, C. W., Brais, L. K., Chan, J. A., Hodi, F. S., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001150 · Cited by 96
DNA repair defects and implications for immunotherapy
Bever, K. M., & Le, D. T. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122010 · Cited by 101
Boilève, A., Carlo, M. I., Barthélémy, P., Oudard, S. M., Borchiellini, D., Voss, M. H., George, S., Chevreau, C., Landman‐Parker, J., Tabone, M.-D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0482-z · Cited by 97
“correlated with response to ICIs in several tumor types [22, 23].”
BackgroundHomologous recombination deficiency in triple negative breast cancer
Belli, C., Duso, B. A., Ferraro, E., & Curigliano, G. (2019) · The Breast · doi:10.1016/j.breast.2019.02.007 · Cited by 108
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
Sheffer, M., Lowry, E., Beelen, N. A., Borah, M., Amara, S. N.-A., Mader, C. C., Roth, J. A., Tsherniak, A., Freeman, S. S., Dashevsky, O., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00889-w · Cited by 101
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 101
The role of the tumour microenvironment in immunotherapy
Gasser, S., Lim, L. H. K., & Cheung, F. S. G. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0146 · Cited by 98
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 92
Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
Croce, M., Ferrini, S., Pfeffer, U., & Gangemi, R. M. R. (2019) · Cancers · doi:10.3390/cancers11060846 · Cited by 100
“A high mutational load may result in the frequent generation of neo-antigens, which render the cutaneous melanoma highly immunogenic and sensitive to immune-checkpoint blockers such as anti-CTLA-4 [18,19] and anti-PD-1 monoclonal antibodies [20,21].”
BackgroundSato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
Conforti, F., Pala, L., Pagan, E., Corti, C., Bagnardi, V., Queirolo, P., Catania, C., Pas, T. M. D., & Giaccone, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100251 · Cited by 97
“A high tumor mutational burden (TMB) is a well-known predictor of benefit from immune checkpoint inhibitors (ICIs) across multiple, yet not all, cancer types.(19,20) Interestingly, a significantly higher TMB has been reported in male patients’ tumors of several histotypes, including melanoma and non-small-cell lung ca…”
BackgroundLee, K., Cutsem, E. V., Bang, Y., Fuchs, C. S., Kudaba, I., Garrido, M., Chung, H. C., Lee, J., Castro, H. R., Chao, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0121 · Cited by 93
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 91
“In melanoma, the tumor mutational burden and number of predicted neoantigens correlate with clinical response to ipilimumab (anti-CTLA-4) [37,38].”
BackgroundThe perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
“The clinical response to ICI treatment indeed correlates with neoantigen load in patients with melanoma [13], non-smallcell lung cancer (NSCLC) [14], and colorectal cancer [15].”
BackgroundZamora, A. E., Crawford, J. C., Allen, E. K., Guo, X.-Z. J., Bakke, J., Carter, R. A., Abdelsamed, H. A., Moustaki, A., Li, Y., Chang, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8549 · Cited by 100
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 91
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 106
“While a significant fraction of FOXA1 mutations in cancer are C-terminal truncation mutations (29, 30), we demonstrated that different from the SBR-deficient mutant FOXA1 (1-247), the two PCa-associated C-terminal truncation mutants FOXA1 (1-290) and FOXA1 (1-268) (29, 30) remained the ability to bind to STAT2 and sup…”
BackgroundAddressing intra-tumoral heterogeneity and therapy resistance
Rybinski, B., & Yun, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11875 · Cited by 107
“A relatively consistent marker for improved clinical response to immune checkpoint blockade in melanoma and NSCLC is a higher tumor mutation and neoantigen load [40-44].”
BackgroundGene-expression profiling to predict responsiveness to immunotherapy
Jamieson, N. B., & Maker, A. V. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.63 · Cited by 92
“Through the development of next generation sequencing (NGS) technologies including whole genome sequencing (WGS) and RNAseq, a high mutational burden of greater than 100 non-synonymous single-nucleotide variants (nsSNV) per exome could be defined and found to be associated with improved clinical outcome in melanoma pa…”
InfluentialTP53 Mutations Promote Immunogenic Activity in Breast Cancer
Liu, Z., Jiang, Z., Gao, Y., Wang, L., Chen, C., & Wang, X. (2018) · Journal of Oncology · doi:10.1155/2019/5952836 · Cited by 98
“For example, high tumor mutation burden (TMB) and neoantigen load, MMR deficiency, and expression of PD-1, PD-1 ligands or cytolytic markers in the TIM were associated with positive clinical response to immune checkpoint blockade in cancers [12-17].”
BackgroundWood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 99
“Availability of data and materials Data used in these analyses is available on the Sequence Read Archive under accessions PRJNA278450 [4], PRJNA293912 [3], PRJNA305077 [68], PRJNA306070 [6], PRJNA307199 [5], PRJNA312948 [5], PRJNA324705 [12], PRJNA343789 [5], PRJNA357321 [13], PRJNA369259 [14], PRJNA414014 [16], PRJNA…”
BackgroundMethodOncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
Hwang, J. K., Hong, J., & Yun, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228627 · Cited by 99
Base editing screens map mutations affecting interferon-γ signaling in cancer
Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 102
“We also discovered a splice mutation in JAK1 as a LOF variant (Arg110 splice variant); however, this tumor mutation was recorded in a patient with a partial response to anti-CTLA-4.(56) This highlights that the presence or absence of LOF variants in the IFN-g pathway in a tumor biopsy is not an absolute determinant of…”
BackgroundScholtalbers, J., Boegel, S., Bukur, T., Byl, M., Goerges, S., Sorn, P., Loewer, M., Sahin, U., & Castle, J. C. (2015) · Genome Medicine · doi:10.1186/s13073-015-0240-5 · Cited by 89
“The number of neo-antigens are further associated with the overall survival of cancer patients [7] and the clinical response to CTLA-4 and PD-1 checkpoint blockade in melanoma patients [8–10].”
BackgroundAssociation ofMUC16Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
Zhang, L., Han, X., & Shi, Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13201 · Cited by 115
Leong, A., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228689 · Cited by 101
The tumor microenvironment and immune responses in prostate cancer patients
Kwon, J., Bryant, R. J., & Parkes, E. E. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0149 · Cited by 107
Rennert, H., Eng, K., Zhang, T., Tan, A. Y., Xiang, J., Romanel, A., Kim, R., Tam, W., Liu, Y., Bhinder, B., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.19 · Cited by 85
“Using WES, it is currently feasible to not only detect a rapidly growing set of known clinically relevant mutations but also identify novel or unexpected important variations, including constitutional mutations in cancer predisposing genes, pharmacogenomics variants impacting therapy and discovery of MHC neoepitope pe…”
de Assis, L. V. M., Kinker, G. S., Moraes, M. N., Markus, R. P., Fernandes, P. A. C. M., & Castrucci, A. M. D. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00185 · Cited by 99
Patterns of Genomic Instability in Breast Cancer
Kalimutho, M., Nones, K., Srihari, S., Duijf, P. H. G., Waddell, N., & Khanna, K. K. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.005 · Cited by 101
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 103
Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines
Roudko, V., Bozkus, C. C., Greenbaum, B. D., Lucas, A. L., Samstein, R. M., & Bhardwaj, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757804 · Cited by 104
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet, G., Brown, M., Bozkus, C. C., & Bhardwaj, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210164 · Cited by 97
Kang, J., Lee, J. H., Cha, H., An, J., Kwon, J., Lee, S., Kim, S., Baykan, M. Y., Kim, S. Y., An, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48310-4 · Cited by 106
Exploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 105
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Gross, S., Erdmann, M., Haendle, I., Voland, S., Berger, T., Schultz, E., Strasser, E., Dankerl, P., Janka, R., Schliep, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91438 · Cited by 87
Alterations of DNA damage repair in cancer: from mechanisms to applications
Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2920 · Cited by 87
“Thus, high mutational loads and predicted tumor antigens play important roles in patients’ responses to ICI-based immunotherapy, with various clinical settings having replicated these findings (66-68).”
Immune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
A slow-cycling subpopulation of melanoma cells with highly invasive properties
Perego, M., Maurer, M., Wang, J., Shaffer, S. M., Müller, A. C., Parapatics, K., Li, L., Hristova, D. M., Shin, S. A., Keeney, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.341 · Cited by 91
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
Zhou, C., Wei, Z., Zhang, Z., Zhang, B., Zhu, C., Chen, K., Chuai, G., Qu, S., Xie, L., Gao, Y., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0679-x · Cited by 97
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
“The mutational and neoantigen load (125) and a high ratio of CD8 density in the intratumoral region have also been related to clinical benefit to Ipilimumab in melanoma (126), while PD-L1 staining by IHC alone does not seem to be predictive (127).”
BackgroundLi, Y., Ma, Y., Wu, Z., Zeng, F., Song, B., Zhang, Y., Li, J., Lui, S., & Wu, M. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751407 · Cited by 95
Campbell, K. M., Amouzgar, M., Pfeiffer, S. M., Howes, T. R., Medina, E., Travers, M., Steiner, G., Weber, J. S., Wolchok, J. D., Larkin, J., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.010 · Cited by 92
Wang, H., Li, S., Wang, Q., Jin, Z., Shao, W., Gao, Y., Li, L., Lin, K., Zhu, L., Wang, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd7851 · Cited by 93
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Tekle, G. E., Bernasocchi, T., Unni, A. M., Bertoni, F., Rossi, D., Rubin, M. A., & Theurillat, J.-P. P. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.009 · Cited by 93
Zhang, P., Wang, D., Zhou, G., Jiang, S., Zhang, G., Zhang, L., & Zhang, Z. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010787 · Cited by 100
Tetzlaff, M. T., Singh, R. R., Seviour, E. G., Curry, J. L., Hudgens, C. W., Bell, D., Wimmer, D. A., Ning, J., Czerniak, B. A., Zhang, L., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4759 · Cited by 90
“To the extent that efficacy of immune checkpoint inhibitors correlates with high neoantigen load [50], these findings suggest that immune checkpoint blockade may have utility in SCs with this phenotype.”
BackgroundSridharan, V., Margalit, D. N., Lynch, S. A., Severgnini, M., Zhou, J. M., Chau, N. G., Rabinowits, G., Lorch, J. H., Hammerman, P. S., Hodi, F. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.166 · Cited by 92
“Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.”
BackgroundHypermutation and microsatellite instability in gastrointestinal cancers
Yuza, K., Nagahashi, M., Watanabe, S., Takabe, K., & Wakai, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22783 · Cited by 86
“Furthermore, studies have indicated an association between elevated mutation burden and response to checkpoint blockade immunotherapy in certain solid cancers [5, 6, 10, 11].”
BackgroundWhen Genome Maintenance Goes Badly Awry
Kass, E. M., Moynahan, M. E., & Jasin, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.021 · Cited by 88
“In studies of melanoma patients, a higher mutational load was associated with a more sustained response to anti-CTLA-4 treatment, and patients benefiting themost had a high neoantigen load that could lead to T cell activation (Snyder et al., 2014; Van Allen et al., 2015).”
Gene fusion neoantigens: Emerging targets for cancer immunotherapy
Wang, Y., Shi, T., Song, X., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.023 · Cited by 84
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Barèche, Y., Kelly, D., Aghababazadeh, F. A., Nakano, M., Esfahani, P. N., Tkachuk, D., Mohammad, H., Samstein, R. M., Lee, C., Morris, L. G. T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.084 · Cited by 89
Zhang, P., Pei, S., Gong, Z., Feng, Y., Zhang, X., Yang, F., & Wang, W. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1115272 · Cited by 86
“The Cancer Immunome Atlas (TCIA) database was used to retrieve the Immunophenoscores (IPS) for LUAD (30).”
MethodZhang, L., Cui, Y., Zhou, G., Zhang, Z., & Zhang, Z. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010008 · Cited by 102
Sun, S., Liu, L., Zhang, J., Sun, L., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01732-z · Cited by 112
“For instance, in non-small cell lung cancer (NSCLC) and melanoma, patients exhibiting high TNB demonstrate enhanced responses to PD-1/CTLA-4 inhibitors and prolonged progression-free survival (PFS) [67, 116].”
Nonomura, Y., Otsuka, A., Nakashima, C., Seidel, J. A., Kitoh, A., Dainichi, T., Nakajima, S., Sawada, Y., Matsushita, S., Aoki, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248327 · Cited by 83
Chen, Y., Huang, Y., Gao, X., Li, Y., Lin, J., Chen, L., Chang, L., Chen, G., Guan, Y., Pan, L. K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01620 · Cited by 100
“The Allen cohort (14) included 72 patients with melanoma treated with anti-CTLA-4, among whom six patients were classified as CCND1 amplification; their disease-free survival (DFS) was inferior to that of 66 patients with the neutral phenotype [2.”
BackgroundMethodAnagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J.-W., Stein, J. E., Tsai, H., Wang, H., Belcaid, Z., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100139 · Cited by 88
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 95
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 90
“TMB Total number of mutations per DNA coding region Melanoma: higher TMB was associated with longer overall survival, clinical benefit with anti-CTLA-4, and response to anti-PD-1/PD-L1 therapies (10-12)”
BackgroundKeilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K.-W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0459-y · Cited by 82
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.